Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
$3.67
-$0.06(-1.81%)
At close: 4:00 PM EST
$3.67
-$0.06(-1.81%)
Day’s Range― - ―
52-Week Range$2.03 - $9.24
Previous CloseN/A
Volume59.09K
Average Volume (3M)150.61K
Market Cap
$198.20M
Enterprise Value$147.01M
Total Cash (Recent Filing)$91.97M
Total Debt (Recent Filing)$40.77M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding54,005,985
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit2.21
Enterprise Value/Ebitda-4.02
Forecast
1Y Price Target
$8.83Price Target Upside140.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$85.42M
Bulls Say, Bears Say
Bulls Say
Dry Eye AdoptionHigh physician satisfaction with TearCare and widespread clinician view of many patients as good candidates position the therapy as a meaningful procedural alternative to prescription drops and support significant adoption potential.
ReimbursementMedicare administrative contractor coverage and an established Medicare fee schedule for TearCare improve payor access and support a clearer path to higher procedure volumes and better gross margins.
Standalone MIGS GrowthA targeted pilot program to build a standalone MIGS market, combined with OMNI's differentiated goniotomy positioning, could drive surgeon engagement and expand surgical glaucoma revenue beyond combo-cataract procedures.
Bears Say
Competitive PressureIntensifying competition from larger medtech and pharmaceutical companies introducing new glaucoma and dry eye treatments could pressure pricing, reimbursement, and market share, limiting growth prospects.
Customer AttritionA decline in surgical glaucoma customers raises the risk of market share loss within a one-MIGS environment and could negatively affect procedure volumes and revenue momentum.
Guidance And Operational UncertaintyConservative management guidance, absence of formal next‑fiscal‑year guidance, and exposure to weather‑related disruptions increase uncertainty about future performance and upside potential.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.03 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $198.20M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is May 13, 2026 which is in 59 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Mar 04, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.139 by $0.059.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.16.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 54,005,985 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.139. Following the earnings report the stock price went down -26.802%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.83 (140.60% Upside)
$8.83 (140.60% Upside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $761.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
-55.72%
Trailing 12-Months
Asset Growth
-19.28%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
SGHT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed constructive operational momentum: revenue growth (+7% Q4), strong 87% gross margins, meaningful operating expense reductions (total OpEx -25%, adjusted OpEx -23%), narrowing net loss, and a major reimbursement milestone (two MACs) enabling a reimbursed TearCare launch. Management provided prudent 2026 guidance ($82M–$88M) that anticipates growth in both Interventional Glaucoma and a scaled Interventional Dry Eye business ($5M–$7M), while also planning targeted commercial and market-access investments. Key risks remain: TearCare is still early-stage and dependent on additional payer wins and commercial scale, cash declined year-over-year and the company remains GAAP-loss-making, and potential future reimbursement code changes (goniotomy) could pressure aspects of the glaucoma market. Overall, positive execution and clear growth initiatives outweigh the remaining operational and reimbursement risks, but realization of the upside depends on successful market access and scaling execution.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$8.83
▲(140.60% Upside)
Technical Analysis
Ownership Overview
35.04% Insiders
5.62% Mutual Funds
13.61% Other Institutional Investors
38.70% Public Companies and
Individual Investors